755 related articles for article (PubMed ID: 20361178)
1. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009.
DeFronzo RA
Diabetologia; 2010 Jul; 53(7):1270-87. PubMed ID: 20361178
[TBL] [Abstract][Full Text] [Related]
2. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players.
Zimmet P; Boyko EJ; Collier GR; de Courten M
Ann N Y Acad Sci; 1999 Nov; 892():25-44. PubMed ID: 10842650
[TBL] [Abstract][Full Text] [Related]
3. Insulin Resistance, Obesity and Lipotoxicity.
Yazıcı D; Sezer H
Adv Exp Med Biol; 2017; 960():277-304. PubMed ID: 28585204
[TBL] [Abstract][Full Text] [Related]
4. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes.
Meex RCR; Blaak EE; van Loon LJC
Obes Rev; 2019 Sep; 20(9):1205-1217. PubMed ID: 31240819
[TBL] [Abstract][Full Text] [Related]
5. Ceramides in insulin resistance and lipotoxicity.
Summers SA
Prog Lipid Res; 2006 Jan; 45(1):42-72. PubMed ID: 16445986
[TBL] [Abstract][Full Text] [Related]
6. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
Leiter LA; Lewanczuk RZ
Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus.
Kawashima Y; Chen J; Sun H; Lann D; Hajjar RJ; Yakar S; Leroith D
Diabetologia; 2009 Jul; 52(7):1434-41. PubMed ID: 19436992
[TBL] [Abstract][Full Text] [Related]
8. Diabetes and branched-chain amino acids: What is the link?
Bloomgarden Z
J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
[TBL] [Abstract][Full Text] [Related]
9. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
Cusi K
Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
[TBL] [Abstract][Full Text] [Related]
10. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.
Bajaj M; Baig R; Suraamornkul S; Hardies LJ; Coletta DK; Cline GW; Monroy A; Koul S; Sriwijitkamol A; Musi N; Shulman GI; DeFronzo RA
J Clin Endocrinol Metab; 2010 Apr; 95(4):1916-23. PubMed ID: 20157197
[TBL] [Abstract][Full Text] [Related]
11. Cellular Senescence in Diabetes Mellitus: Distinct Senotherapeutic Strategies for Adipose Tissue and Pancreatic β Cells.
Murakami T; Inagaki N; Kondoh H
Front Endocrinol (Lausanne); 2022; 13():869414. PubMed ID: 35432205
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Højlund K
Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance, diabetes, and the adipocyte.
Stolar MW
Am J Health Syst Pharm; 2002 Dec; 59 Suppl 9():S3-8. PubMed ID: 12489380
[TBL] [Abstract][Full Text] [Related]
14. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
Mensink M; Hesselink MK; Russell AP; Schaart G; Sels JP; Schrauwen P
Int J Obes (Lond); 2007 Aug; 31(8):1302-10. PubMed ID: 17310221
[TBL] [Abstract][Full Text] [Related]
15. Ectopic lipid accumulation: A potential cause for metabolic disturbances and a contributor to the alteration of kidney function.
Guebre-Egziabher F; Alix PM; Koppe L; Pelletier CC; Kalbacher E; Fouque D; Soulage CO
Biochimie; 2013 Nov; 95(11):1971-9. PubMed ID: 23896376
[TBL] [Abstract][Full Text] [Related]
16. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
Gastaldelli A; Harrison SA; Belfort-Aguilar R; Hardies LJ; Balas B; Schenker S; Cusi K
Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
[TBL] [Abstract][Full Text] [Related]
17. Acetyl-CoA carboxylase 2 inhibition reduces skeletal muscle bioactive lipid content and attenuates progression of type 2 diabetes in Zucker diabetic fatty rats.
Takagi H; Ikehara T; Hashimoto K; Tanimoto K; Shimazaki A; Kashiwagi Y; Sakamoto S; Yukioka H
Eur J Pharmacol; 2021 Nov; 910():174451. PubMed ID: 34454928
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic β-cell dysfunction via regulation of AMPK signaling and lipid metabolism.
Xie T; So WY; Li XY; Leung PS
Clin Sci (Lond); 2019 Oct; 133(19):2029-2044. PubMed ID: 31654570
[TBL] [Abstract][Full Text] [Related]
19. Lipid accumulation in non-adipose tissue and lipotoxicity.
van Herpen NA; Schrauwen-Hinderling VB
Physiol Behav; 2008 May; 94(2):231-41. PubMed ID: 18222498
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases.
Cersosimo E; DeFronzo RA
Diabetes Metab Res Rev; 2006; 22(6):423-36. PubMed ID: 16506274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
